Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mayne buys back US Doryx rights from Actavis for $50mm

Executive Summary

Actavis PLC divested to Mayne Pharma Group Ltd. its US rights to the tetracycline antibiotic Doryx (delayed-release doxycycline) for severe acne. Mayne, which originally developed the drug, paid $50mm and also gets the product's trademark, marketing materials, inventory, and medical and technical data.

Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies